The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
.
Recent Transactions
Sort By
27-Apr-21
$4.2 billion
Target:
AMP Capital Diversified Property Fund
Acquiror:
Dexus and Dexus Wholesale Property Fund
Advised ASX-listed real estate investment trust Dexus and its unlisted diversified property fund, Dexus Wholesale Property Fund, on Dexus Wholesale Property Fund’s merger with AMP Capital Diversified Property Fund
28-Oct-20
Undisclosed
Target:
Easton Investments Limited
Acquiror:
HUB24 Limited
Advising HUB24 Limited (ASX: HUB), a leading specialist investment platform provider, on its proposed acquisition of up to 40% in Easton Investments Limited (ASX: EAS), a leading provider of wealth and accounting solutions. The transaction also included the divestment of HUB24’s subsidiary, Paragem, to Easton
31-Jan-20
$NA
Target:
50:50 Joint Venture (Australian Unity)
Acquiror:
Keppel Capital Holdings
Advised Australian Unity, an Australian healthcare, financial services and retirement and living services company, on the formation of a strategic 50:50 joint venture with Keppel for investment opportunities in the Australian metropolitan office property sector
23-Aug-19
$NA
Target:
TT International
Acquiror:
Sumitomo Mitsui Financial Group, Inc.
Advised TT International, a leading independent asset management firm focused on managing high alpha, high conviction active management strategies for institutional investors, on its sale to Sumitomo Mitsui Financial Group, Inc.
02-May-19
$1.0 billion
Target:
80 Collins Precinct
Acquiror:
Dexus
Advised Dexus in relation to its acquisition of the 80 Collins precinct from QIC Global Real Estate
19-Mar-19
$NA
Target:
BT Advice
Acquiror:
Viridian Advisory
Advised Westpac, the third largest company in Australia by market capitalization, on its exit of BT Advice and the sale of select assets to Viridian Advisory
19-Dec-18
$NA
Target:
Starpharma Holdings Limited, patented VivaGel BV® product
Acquiror:
ITF Pharma, US subsidiary of Italfarmaco S.p.A.
Advised Starpharma Holdings Limited on a US licensing agreement of its patented VivaGel BV® product with ITF Pharma, a US subsidiary of Italfarmaco S.p.A., a privately held European specialty pharmaceutical company
24-Oct-18
$41 million
Target:
TeePublic
Acquiror:
Redbubble
Advised Redbubble, a global online independent artist community and marketplace, on the acquisition of TeePublic, a similar online platform, and associated A$61 million equity raising
10-Sep-18
$100 million
Target:
Montserrat Day Hospital Group
Acquiror:
Primary Health Care
Advised ASX-listed Primary Health Care, one of Australia’s leading providers of multi-disciplinary healthcare services, on its acquisition of the Montserrat Day Hospital Group, an owner and operator of day hospital facilities
08-Aug-18
$538 million
Target:
Suncorp Group Limited’s Australian Life Insurance Business
Acquiror:
TAL
Advised TAL, Australia’s largest and leading insurance business that is 100% owned by Dai-ichi Life of Japan, on the acquisition of Suncorp Group Limited’s Australian Life Insurance business
23-Nov-16
$NA
Target:
Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.
Acquiror:
Arrow Generiques SAS
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).
28-Jun-16
$652 million
Target:
US rights to 37 approved and 5 pipeline generic products
Acquiror:
Mayne Pharma Group Limited
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
28-Jul-14
$90 million
Target:
Clinuvel Pharmaceuticals Limited
Acquiror:
Retrophin, Inc.
Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases
11-Apr-14
$414 million
Target:
Investec Bank (Australia) Limited
Acquiror:
Bank of Queensland Limited
Advised Investec Bank (Australia) Limited on the sale of its Professional Finance and Asset Finance and Leasing businesses, its deposit book, and its Australian banking licence to Bank of Queensland Limited (“BOQ”). BOQ is a leading regional Australian bank which provides retail and business banking
31-May-13
$57 million
Target:
d-cyphaTrade Limited
Acquiror:
Australian Securities Exchange (ASX)
Advised Transpower New Zealand, the state owned owner-operator of New Zealand’s electricity distribution network on the sale of its wholly owned subsidiary d-cyphaTrade Limited to the Australian Securities Exchange. d-cyphaTrade specializes in the design and marketing of Australian electricity derivatives traded on the ASX24 derivatives platform
31-May-13
$500 million
Target:
iSelect (30% shareholding)
Acquiror:
Ninemsn (T/A Mi9)
Advised Mi9, a joint venture between Microsoft and Nine Entertainment Co, and one of Australia’s leading digital media companies, on the sale of its 30% holding in iSelect, a leading Australian online-driven comparison service, as part of the Initial Public Offering of iSelect
21-Nov-11
$689 million
Target:
iNova Pharmaceuticals
Acquiror:
Valeant Pharmaceuticals
Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals
26-May-11
$192 million
Target:
Centrebet International Limited
Acquiror:
Sportingbet plc
Advised Centrebet International, a leading International online wagering and gaming operator on the recommended cash offer by Sportingbet plc
01-Mar-11
$128 million
Target:
Tyndall Investments
Acquiror:
Nikko Asset Management
Advised Suncorp, on the sale of its investment management business, Tyndall Investments, in Australia and New Zealand to Nikko Asset Management, a leading Asian mutual funds management company
29-Dec-10
$1.8 billion
Target:
TOWER Australia Group Limited
Acquiror:
The Dai-ichi Life Insurance Company, Limited
Advised TOWER Australia Group Limited, the largest mono-line life insurance company in Australia, in relation to the offer from The Dai-ichi Life Insurance Company, Limited to acquire all of the shares in TOWER that it does not already own by way of a scheme of arrangement
26-Nov-10
$118 million
Target:
Healthcare Australia
Acquiror:
Healthcare Locums
Advised CHAMP Private Equity on the sale of Healthcare Australia, a leading provider of nursing agency staff to public and private health institutions in Australia, to Healthcare Locums, a healthcare recruitment agency based in the UK
26-Oct-10
$175 million
Target:
Rural Bank
Acquiror:
Bendigo and Adelaide Bank
Advised Elders, a diversified agricultural company on the sale of its 40% stake in Rural Bank to Bendigo and Adelaide Bank, an Australian diversified financial services company
23-Sep-10
$394 million
Target:
Aevum Ltd.
Acquiror:
Stockland Corp. Ltd
Advised Aevum Limited, an ASX listed owner, operator and developer of retirement villages and aged care facilities on its response to a hostile takeover offer from Stockland Ltd, a global property development and investment management group
28-May-09
$107 million
Target:
Tristone Capital Global Inc.
Acquiror:
Macquarie Group
Advised Tristone Capital Global Inc., an independent advisory firm focused on the global energy sector, on its sale to Macquarie Group